Karyopharm Therapeutics Inc. (NASDAQ:KPTI) went down by -6.68% from its latest closing price compared to the recent 1-year high of $18.00. The company’s stock price has collected -1.06% of loss in the last five trading sessions. Press Release reported on 09/07/21 that Karyopharm Announces Upcoming Virtual Investor Conference Participation
Is It Worth Investing in Karyopharm Therapeutics Inc. (NASDAQ :KPTI) Right Now?
Plus, the 36-month beta value for KPTI is at 0.20. Opinions of the stock are interesting as 4 analysts out of 10 who provided ratings for Karyopharm Therapeutics Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $15.22. KPTI currently public float of 68.11M and currently shorts hold a 20.45% ratio of that float. Today, the average trading volume of KPTI was 1.50M shares.
KPTI’s Market Performance
KPTI stocks went down by -1.06% for the week, with a monthly jump of 14.55% and a quarterly performance of -44.16%, while its annual performance rate touched -63.42%. The volatility ratio for the week stands at 6.39% while the volatility levels for the past 30 days are set at 6.79% for Karyopharm Therapeutics Inc.. The simple moving average for the period of the last 20 days is 4.54% for KPTI stocks with a simple moving average of -49.77% for the last 200 days.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with SVB Leerink repeating the rating for KPTI by listing it as a “Mkt Perform.” The predicted price for KPTI in the upcoming period, according to SVB Leerink is $6 based on the research report published on August 06th of the current year 2021.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $8, previously predicting the price at $17. The rating they have provided for KPTI stocks is “Sector Perform” according to the report published on August 06th, 2021.
KPTI Trading at -21.01% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.94% of loss for the given period.
Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares surge +20.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.81% lower at present.
During the last 5 trading sessions, KPTI fell by -1.06%, which changed the moving average for the period of 200-days by -62.10% in comparison to the 20-day moving average, which settled at $5.39. In addition, Karyopharm Therapeutics Inc. saw -63.89% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at KPTI starting from Mitchener Stephen, who sale 528 shares at the price of $9.29 back on Jun 02. After this action, Mitchener Stephen now owns 2,472 shares of Karyopharm Therapeutics Inc., valued at $4,905 using the latest closing price.
Shah Jatin, the EVP, Chief Medical Officer of Karyopharm Therapeutics Inc., purchase 23,250 shares at $8.60 during a trade that took place back on May 07, which means that Shah Jatin is holding 131,802 shares at $199,992 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -159.00 for the present operating margin
- +96.60 for the gross margin
The net margin for Karyopharm Therapeutics Inc. stands at -181.59. The total capital return value is set at -96.50, while invested capital returns managed to touch -111.33.
Based on Karyopharm Therapeutics Inc. (KPTI), the company’s capital structure generated 259.43 points at debt to equity in total, while total debt to capital is 72.18. Total debt to assets is 41.89, with long-term debt to equity ratio resting at 255.63. Finally, the long-term debt to capital ratio is 71.12.
When we switch over and look at the enterprise to sales, we see a ratio of 9.20, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 10.42 and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.